These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
121 related articles for article (PubMed ID: 1346511)
1. Effect of xamoterol in Shy-Drager syndrome. Obara A; Yamashita H; Onodera S; Yahara O; Honda H; Hasebe N Circulation; 1992 Feb; 85(2):606-11. PubMed ID: 1346511 [TBL] [Abstract][Full Text] [Related]
2. Xamoterol in the treatment of orthostatic hypotension associated with multiple system atrophy (Shy-Drager syndrome). West JN; Stallard TJ; Dimmitt SB; Smith SA; Williams A; Littler WA Q J Med; 1990 Feb; 74(274):209-13. PubMed ID: 1971724 [TBL] [Abstract][Full Text] [Related]
3. A double-blind crossover study of oral xamoterol in postural hypotension due to diabetic autonomic neuropathy. Leslie PJ; Thompson C; Clarke BF; Ewing DJ Clin Auton Res; 1991 Jun; 1(2):119-23. PubMed ID: 1688039 [TBL] [Abstract][Full Text] [Related]
4. Hemodynamic effects of the beta 1-adrenoceptor partial agonist xamoterol in relation to plasma norepinephrine levels during exercise in patients with left ventricular dysfunction. Sato H; Inoue M; Matsuyama T; Ozaki H; Shimazu T; Takeda H; Ishida Y; Kamada T Circulation; 1987 Jan; 75(1):213-20. PubMed ID: 2878742 [TBL] [Abstract][Full Text] [Related]
5. Xamoterol, a new selective beta-1-adrenoceptor partial agonist, in the treatment of postural hypotension. Mehlsen J; Trap-Jensen J Acta Med Scand; 1986; 219(2):173-7. PubMed ID: 2870611 [TBL] [Abstract][Full Text] [Related]
6. Beta-adrenergic blood pressure regulation in Shy-Drager syndrome and pheochromocytoma. Middeke M; Ittner J; Mezger M; Reder S; Remien J Klin Wochenschr; 1989 Oct; 67(19):1004-9. PubMed ID: 2559241 [TBL] [Abstract][Full Text] [Related]
7. Lack of tolerance development after long-term administration of the partial beta-adrenoceptor agonist xamoterol. Erlemeier HH; Kupper W; Bleifeld W Cardiology; 1990; 77(1):30-9. PubMed ID: 1972349 [TBL] [Abstract][Full Text] [Related]
8. Comparative analysis of beta-1 adrenoceptor agonist and antagonist potency and selectivity of cicloprolol, xamoterol and pindolol. Hicks PE; Cavero I; Manoury P; Lefevre-Borg F; Langer SZ J Pharmacol Exp Ther; 1987 Sep; 242(3):1025-34. PubMed ID: 2888869 [TBL] [Abstract][Full Text] [Related]
9. Cardioselectivity, kinetics, hemodynamics, and metabolic effects of xamoterol. Jennings G; Bobik A; Oddie C; Restall R Clin Pharmacol Ther; 1984 May; 35(5):594-603. PubMed ID: 6143634 [TBL] [Abstract][Full Text] [Related]
10. Selective beta-adrenoceptor partial agonist effects of pindolol and xamoterol on skeletal muscle assessed by plasma creatine kinase changes in healthy subjects. Tomlinson B; Cruickshank JM; Hayes Y; Renondin JC; Lui JB; Graham BR; Jones A; Lewis AD; Prichard BN Br J Clin Pharmacol; 1990 Nov; 30(5):665-72. PubMed ID: 1980200 [TBL] [Abstract][Full Text] [Related]
11. Haemodynamics in postural hypotension--effects of the beta-adrenoceptor partial agonist xamoterol, and pindolol. Mehlsen J; Trap-Jensen J Eur Heart J; 1990 Apr; 11 Suppl A():56-8. PubMed ID: 1971593 [TBL] [Abstract][Full Text] [Related]
12. [Assessment of chronotropic effect and arrhythmogenesis on beta 1-partial agonist (Xamoterol) in chronic heart failure]. Fukuda K; Handa S; Ogawa S; Nakamura Y; Kawamura Y Kokyu To Junkan; 1988 Nov; 36(11):1227-33. PubMed ID: 2907820 [No Abstract] [Full Text] [Related]
13. Effects of xamoterol in acute myocardial infarction: blood pressure, heart rate, arrhythmias and early clinical course. McMurray J; Lang CC; MacLean D; Struthers AD; McDevitt DG Int J Cardiol; 1991 Jun; 31(3):295-303. PubMed ID: 1679047 [TBL] [Abstract][Full Text] [Related]
14. The effects of the partial beta 1-agonist xamoterol on heart rate and ventricular arrhythmias in patients with mild to moderate heart failure. Virk SJ; Anfilogoff NH; Lawson N; Qiang F; Murray RG; Littler WA; Davies MK Eur Heart J; 1990 Oct; 11(10):876-84. PubMed ID: 1979946 [TBL] [Abstract][Full Text] [Related]
15. Agonist-induced desensitization of beta-adrenoceptor function in humans. Subtype-selective reduction in beta 1- or beta 2-adrenoceptor-mediated physiological effects by xamoterol or procaterol. Brodde OE; Daul A; Michel-Reher M; Boomsma F; Man in 't Veld AJ; Schlieper P; Michel MC Circulation; 1990 Mar; 81(3):914-21. PubMed ID: 1968366 [TBL] [Abstract][Full Text] [Related]
16. Effects of xamoterol on resting and exercise haemodynamics in patients with chronic heart failure. Virk SJ; Davies MK Br J Clin Pharmacol; 1989; 28 Suppl 1(Suppl 1):15S-22S. PubMed ID: 2572250 [TBL] [Abstract][Full Text] [Related]
17. Effects of xamoterol a new beta-adrenoceptor partial agonist, in patients with angina pectoris. Barrios L; Geboers J; Piessens JH; de Geest H Eur J Clin Pharmacol; 1986; 29(6):667-71. PubMed ID: 2872055 [TBL] [Abstract][Full Text] [Related]
18. [Noninvasive evaluation of partial beta adrenergic agonist properties of xamoterol in cardiac insufficiency]. Richaud M; Lechat P; Komajda M; Landault C; Fournier P; Fraysse JB; Grosgogeat Y Arch Mal Coeur Vaiss; 1990 Feb; 83(2):247-52. PubMed ID: 1968739 [TBL] [Abstract][Full Text] [Related]
19. Effect of xamoterol in a patient with idiopathic autonomic failure. Elizabeth J; Solomon LR; Lye M J Auton Nerv Syst; 1992 Apr; 38(1):65-8. PubMed ID: 1350286 [TBL] [Abstract][Full Text] [Related]
20. A comparative study on the ventilatory and haemodynamic effects of xamoterol and atenolol in asthmatic patients. Lammers JW; Müller ME; Folgering HT; van Herwaarden CL Br J Clin Pharmacol; 1986 Nov; 22(5):595-602. PubMed ID: 2878680 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]